Tudor Investment Corp’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Tudor Investment Corp’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-640	Closed	-$63K	–	1924
2020 Q4	$63K	Buy	+640	New	+$40.5K	﹤0.01%	1282
2016 Q4	–	Sell	-24	Closed	-$27K	–	1657
2016 Q3	$27K	Hold	24	–	–	﹤0.01%	1386
2016 Q2	$19K	Hold	24	–	–	﹤0.01%	1569
2016 Q1	$17K	Hold	24	–	–	﹤0.01%	1683
2015 Q4	$24K	Hold	24	–	–	﹤0.01%	1598
2015 Q3	$26K	Hold	24	–	–	﹤0.01%	1491
2015 Q2	$50K	Hold	24	–	–	﹤0.01%	1443
2015 Q1	$23K	Hold	24	–	–	﹤0.01%	1415
2014 Q4	$25K	Sell	24 -2	-8%	-$1.78K	﹤0.01%	1413
2014 Q3	$27K	Sell	26 -6	-19%	-$8.85K	﹤0.01%	1320
2014 Q2	$61K	Hold	32	–	–	﹤0.01%	1115
2014 Q1	$68K	Hold	32	–	–	﹤0.01%	1142
2013 Q4	$73K	Buy	+32	New	+$73.2K	﹤0.01%	1219

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $4.53B AUM 21.1% 1-Year Est. Return

Tudor Investment Corp's ONCT Position: Q1 2021 in Review

Tudor Investment Corp sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 640 shares — an estimated $63K sold.

Tudor Investment Corp first reported a position in ONCT in Q4 2013 and held it in 13 quarters. The position peaked at $73K in Q4 2013. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

Tudor Investment Corp reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Tudor Investment Corp sold 640 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $63K.
Tudor Investment Corp first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2013 and held it in 13 quarters.
Tudor Investment Corp's Oncternal Therapeutics, Inc. Common Stock position peaked at $73K in Q4 2013.
64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Tudor Investment Corp's 13F filing for Q1 2021, filed 17 May 2021.